Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentolinium is a ganglionic blocking agent used primarily as an antihypertensive drug. It acts as a nicotinic acetylcholine receptor antagonist, specifically targeting neuronal nicotinic receptors (notably alpha 3 beta 4 subtypes) at autonomic ganglia. By binding to these receptors, pentolinium inhibits the release of noradrenaline and adrenaline from adrenergic nerves, leading to smooth muscle relaxation and vasodilation. This mechanism results in lowered blood pressure and makes it useful for managing acute or chronic hypertension, particularly during surgery or hypertensive crises. Pentolinium is typically administered orally, intramuscularly, or intravenously[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentolinium.